Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
GSK is a global pharmaceutical company that makes prescription medicines, vaccines, and specialty drugs to treat diseases like asthma, HIV, cancer, and immune disorders.
GSK is a British drugmaker that sells the medicines and vaccines that doctors prescribe and health systems pay for. Its biggest business is vaccines — it is one of the largest vaccine makers in the world, selling shots for shingles, flu, meningitis, and RSV, the respiratory virus that hits older adults hard. Its second big engine is specialty medicines: HIV treatments, cancer drugs, and medicines for immune and respiratory diseases like asthma. It also still sells a large portfolio of older, everyday prescription drugs.
The way the money works is simple. GSK spends years and billions developing a drug or vaccine, gets it approved by regulators, then sells it at a price that covers all that risk and effort. A single shingles vaccine dose can cost well over a hundred dollars, and GSK sells tens of millions of doses a year. HIV is the other crown jewel: GSK's majority-owned HIV unit ViiV makes long-acting treatments that patients take less often than daily pills, which keeps people coming back. GSK owns most of ViiV but not all of it — Pfizer holds a minority stake and collects a share of the profits. The company you see today is the product of a 2022 split. For years it was GlaxoSmithKline, a sprawling giant that also sold toothpaste, pain relievers, and other consumer brands like Sensodyne and Panadol. In 2022 it spun that consumer business off into a separate company called Haleon, keeping the prescription medicines and vaccines. GSK also fought off a huge unwanted takeover approach from Unilever along the way. The result is a leaner company focused purely on science, betting that vaccines and specialty drugs are where the real money and growth live.
GSK's strength is its vaccine franchise and its HIV business, both of which generate steady, high-margin cash. Its weak spot is that it has been seen as a laggard in cancer and has faced big patent expirations on older drugs, which is why it has spent heavily buying new assets. It plows much of its cash into research and deals and pays a sizable dividend — a pitch to investors that says: stable cash today, with a shot at growth if the pipeline delivers. Competitors include AstraZeneca, Merck, Pfizer, and Sanofi, all fighting for the same prescription dollars and vaccine contracts.
Saved answer · last researched 15 Nov 2026